How we choose factor VIII to treat hemophilia
Open Access
- 3 May 2012
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 119 (18), 4108-4114
- https://doi.org/10.1182/blood-2012-01-394411
Abstract
In high-income countries, the large availability of coagulation factors for replacement therapy of patients with hemophilia A has raised the life expectancy of these lifelong bleeders to that of males from the general population. The practicing clinician is offered a multitude of choices among several commercial brands of factor VIII extracted from human plasma or engineered from mammalian cell cultures by means of recombinant DNA technology. This article has the goal to offer our opinions on how to choose among the different products, that we consider interchangeable relevant to their clinical efficacy in the control of bleeding and safety from pathogen transmission. Hence, the main determinants of our choices are price and the risk of occurrence of factor VIII inhibitory alloantibodies. With this as background, we present the rationale underlying the choices for different categories of patients with severe hemophilia A: previously untreated patients, multiply treated patients, and patients undergoing immune tolerance induction with large doses of factor VIII to eradicate inhibitors. Mention is also made to the possible strategies that should be implemented to make available coagulation factors for replacement therapy in developing countries.Keywords
This publication has 66 references indexed in Scilit:
- Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patientsBlood, 2012
- Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia BNew England Journal of Medicine, 2011
- Can B‐domain deletion alter the immunogenicity of recombinant factor VIII? A meta‐analysis of prospective clinical studiesJournal of Thrombosis and Haemostasis, 2011
- The use of a single von Willebrand factor‐containing, plasma‐derived FVIII product in hemophilia A immune tolerance induction: the US experienceJournal of Thrombosis and Haemostasis, 2011
- Concentrate‐related inhibitor risk: is a difference always real?Journal of Thrombosis and Haemostasis, 2011
- Factor VIII inhibitors in previously treated hemophilic patientsJournal of Thrombosis and Haemostasis, 2011
- Plasma and albumin‐free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patientsJournal of Thrombosis and Haemostasis, 2008
- Hemophilia Treatment in Developing Countries: Products and ProtocolsSeminars in Thrombosis and Hemostasis, 2005
- The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99Journal of Thrombosis and Haemostasis, 2004
- Use of Recombinant Antihemophilic Factor in the Treatment of Two Patients with Classic HemophiliaNew England Journal of Medicine, 1989